Clinical trials: High-risk Breast Cancer
Triple-negative Breast Cancer
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
In TNBC patients who have completed neoadjuvant immunotherapy and local treatment, a 9-cycle regimen of PD-1 inhibitor adjuvant immunotherapy is currently considered the standard approach.
- Trial name
- NCT06533384
- Testing
- As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy., 9 cycles of Camrelizumab as adjuvant therapy.
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer
Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy
Objectives: The objective of this single-arm, prospective study is to perform annual mammography and MRI breast cancer screening in women who underwent mantle-field irradiation between 1970-1995 at M. D.
- Trial name
- NCT00925405
- Testing
- Breast MRI, Mammogram
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
MRD in High-risk EBC
This study is a multicenter, prospective, observational cohort study, 125 patients with early-stage high-risk breast cancer will be enrolled, perioperative surgical specimens, peripheral blood specimens before and after adjuvant…
- Trial name
- NCT06566729
- Testing
- Peripheral blood sample collection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer, Breast Neoplasm
Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients
This research study is designed to work in cooperation with another study being conducted by the National Cancer Institute. The National Cancer Institute (NCI) is studying the effects of a drug called raloxifene on premenopausal…
- Trial name
- NCT00001837
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Breast Cancer, Chemotherapy Effect
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
According to the latest data from the World Health Organization's International Agency for Research on Cancer (IARC) for 2020, breast cancer has been the most prevalent cancer with 2.26 million new cases.
- Trial name
- NCT05212454
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Breast Cancer Invasive
Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer
Breast-conserving surgery (BCS) has become the standard-of-care for surgical management of the majority of women with early-stage breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Invasive, Breast Cancer in Situ
- Trial name
- BrIMA (NCT04999917)
- Testing
- high-resolution PET-CT specimen imaging.
- Where
- Belgium
- Volunteers
- 206 people
- Sponsor
- XEOS Medical
Breast Neoplasms
Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer
This phase I/II clinical trial studies the side effects of delivering radiation therapy in a single session instead of multiple treatments over several weeks and to see how well it works in treating patients with low-risk stage…
- Trial name
- NCT02076074
- Testing
- accelerated partial breast irradiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Microbiome
Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy
Triple-negative breast cancer (TNBC) is considered a tumor with a high risk of recurrence and metastasis and requires aggressive systemic therapy combining immunotherapy and chemotherapy.
- Trial name
- BallastImmun (NCT07311083)
- Testing
- switching to a high-fibre diet, official dietary recommendations
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Kliniken Essen-Mitte
Breast Cancer
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer
RATIONALE: Giving chemotherapy, such as fludarabine and melphalan, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells.
- Trial name
- NCT00074269
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Breast Cancer
Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca
Randomized phase III trial to determine the effectiveness of High dose versus Standard dose of Vitamin D2 (Ergocalciferol) given with Docetaxel in patients with metastatic breast cancer
- Trial name
- GORG-002 (NCT00944424)
- Testing
- Docetaxel + High dose Vitamin D2, Docetaxel + Standard dose Vitamin D2
- Where
- 6 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 260 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Genetic Predisposition, BRCA Mutation
Frequency of Occult Breast Cancer After Prophylactic Mastectomy Among High-Penetrance Breast Cancer Gene Positives
The role of Sentinel Lymph Node Biopsy(SLNB) among mutation-negative BC patients is well established; however, we are lacking data to assess the role of sentinel lymph node biopsy for patients who are undergoing surgery for…
- Conditions
- Genetic Predisposition, BRCA Mutation, Breast Cancer, Occult Cancer
- Trial name
- OBC-PM (NCT05771454)
- Testing
- Histopathological confirmation
- Where
- Pakistan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Aga Khan University Hospital, Pakistan
Breast Cancer Female
Effects of Moderate and High-intensity Exercise During Chemotherapy on Muscle Cells in Women With Breast Cancer
(Neo-)adjuvant chemotherapy for breast cancer has deleterious effects on muscle tissue resulting in reduced skeletal muscle mass, muscle function, and cardiorespiratory fitness.
- Trial name
- PhysCan (NCT05218876)
- Testing
- Low- to moderate intensity strength and endurance training, High intensity strength and endurance training
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Norwegian School of Sport Sciences
Female Breast Cancer
Estrogen for Triple Negative Breast Cancer
The purpose of this study is to determine the effectiveness of Estradiol treatment for advanced breast cancer that is hormone receptor negative and Her2/neu negative.
- Trial name
- NCT01083641
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer, Genetic Susceptibility
ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies
This is a community-based prospective study and the research object is breast cancer patients. It is planned to take the community as the unit to inform and collect the breast cancer patients who voluntarily participate to carry…
- Trial name
- SIGHT (NCT04265937)
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Fudan University
Breast Carcinoma
Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer
This stage I clinical trial compares a genetic counseling patient preference (GCPP) intervention via EHR MyChart patient portal to conventional genetic counseling for women at elevated risk for breast cancer.
- Trial name
- NCT05325151
- Testing
- Educational Intervention, Genetic Counseling, Survey Administration
- Where
- United States
- Volunteers
- 874 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Breast Cancer
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00002627
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- St. Louis University
Breast Cancer
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
RATIONALE: Vaccines may make the body build an immune response and decrease the recurrence of breast cancer. PURPOSE: Pilot trial to study the effectiveness of vaccine therapy in treating patients who are at high risk for breast…
- Trial name
- NCT00030823
- Testing
- Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of LY353381 may be an effective way to prevent the development of breast cancer in women who have…
- Trial name
- NCT00005879
- Testing
- arzoxifene
- Where
- 2 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Breast Cancer, Healthy
Susceptibility to Breast Cancer
This study will explore whether different forms, or variants, of genes are related to a person s risk of developing breast cancer.
- Trial name
- NCT00004565
- Where
- United States
- Volunteers
- 737 people
- Sponsor
- National Cancer Institute (NCI)